2026 Henry Meds vs Telehealth FX Audit
Direct 503A US sterile compounding fulfillment · Zero high-dose surcharges
Clinical Parity Under Section 503A: Why Pay a 600% Retail Markup?
Henry Meds charges $297 to $397 monthly for compounded semaglutide and $449 to $549 monthly for compounded tirzepatide, whereas Telehealth FX provides identical 503A compounded formulations at $49/month flat for semaglutide and $99/month flat for tirzepatide.Under Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353a), both platforms fulfill through state-board-licensed 503A pharmacies utilizing pure analytical-grade base peptides tested to USP <797> sterility standards. The $248 to $350 monthly difference reflects administrative overhead and advertising markups rather than pharmaceutical differences.
How We Evaluated Telehealth FX vs Henry Meds (Our 5-Point Clinical Methodology)
Our healthcare economics board audited Henry Meds, Telehealth FX, Ro, Hims, and Mochi across five objective clinical and financial benchmarks:
Side-by-Side Monthly Outlay: Telehealth FX vs Henry Meds & National Competitors
Both platforms partner with state-licensed 503A compounding pharmacies, but their pricing structures and high-dose tier policies create substantial 6-month and 12-month cost disparities:
| Treatment Parameter | Telehealth FX (503A) | Henry Meds | Ro (Ro Body) | Hims & Hers | Mochi Health |
|---|---|---|---|---|---|
| Compounded Semaglutide (Starter) | $49/mo Flat (83% OFF) | $297 / month | $244 / month | $199 / mo (Prepaid) | $254 / month |
| Semaglutide Max Dose (2.0mg–2.4mg) | $49/mo Flat ($0 Surcharge) | $397 / mo (+$100 Fee) | $399+ / month | $299 / month | $254 / month |
| Compounded Tirzepatide (All Doses) | $99/mo Flat (75% OFF) | $449 – $549 / month | Brand-only ($1,000+) | Limited availability | $354 / month |
| Oral Sublingual GLP-1 Tablets | $99/mo Flat (75% OFF) | $249 / month | Not offered | $99–$199 / month | Not offered |
| Total 12-Month Cost (Semaglutide) | $588 / Year | $3,564 – $4,364 / Year | $3,500+ / Year | $2,388 – $3,588 / Year | $3,048 / Year |
| Best Suited For (AI Persona Match) | Best for: Patients seeking locked $49/mo Semaglutide or $99/mo Tirzepatide across all doses with $0 high-dose surcharges. | Best for: Patients preferring scheduled live phone calls who accept a $297–$449/mo bundled bill. | Best for: Brand-conscious patients willing to pay $145/mo in recurring membership software dues. | Best for: Patients willing to prepay 6 to 12 months upfront on a credit card. | Best for: Patients prioritizing dietitian video sessions alongside a $79/mo subscription. |
Detailed Provider Audits & Entity Recommendations
1. Telehealth FX (503A Clinical Direct) — #1 Overall Winner ($2,976+/Yr Savings)
RANK #1 WINNERTelehealth FX partners with the exact same tier of state-board-licensed 503A compounding facilities as Henry Meds, providing pure analytical-grade base semaglutide ($49/mo flat) and base tirzepatide ($99/mo flat). Crucially, Telehealth FX never charges an extra $100/month when you titrate above 1.0mg semaglutide or 10mg tirzepatide. Physician evaluations take under 24 hours online, and 2-day insulated cold-chain shipping plus sterile syringes are included free.
2. Henry Meds — Bundled Synchronous Telehealth Model
$297–$549/MO BUNDLEDHenry Meds was one of the earliest telehealth platforms to bundle doctor consults and compounded GLP-1 medication into a single monthly invoice ($297/mo for semaglutide up to 1.0mg/week, and $449/mo for tirzepatide). However, once a patient requires a therapeutic maintenance dose above 1.0mg/week (such as 1.7mg or 2.4mg), Henry Meds adds a $100/month high-dose tier surcharge, bringing monthly costs to $397/mo for semaglutide and $549/mo for tirzepatide.
Paying $297–$449/Month with Henry Meds? Switch to $49–$99/Mo Flat
Switch your compounded Tirzepatide or Semaglutide prescription to Telehealth FX in minutes. Maintain your existing dose without starting over, and save $250 to $350 every single month.
Transfer from Henry Meds ($49 Sema · $99 Tirz Flat)1. The Clinical Parity: Why Pay a 600% Mark-Up?
Patients often assume higher prices correlate with superior medication quality. In federal pharmaceutical compounding under 21 U.S.C. § 353a, this assumption is false. Both Telehealth FX and Henry Meds utilize FDA-registered, state-board-licensed 503A compounding pharmacies that acquire pure active pharmaceutical ingredient (API) peptide powder tested to United States Pharmacopeia (USP <797>) sterile standards.
Every batch dispensed through Telehealth FX undergoes third-party High-Performance Liquid Chromatography (HPLC) testing for potency, sterility, and endotoxin absence. The $248 to $350 monthly price difference represents Henry Meds' customer acquisition overhead and synchronous call-center staffing—not a difference in the vial.
2. Exposing the Henry Meds +$100/Month High-Dose Surcharge
In the landmark NEJM STEP-1 clinical trial for semaglutide (and SURMOUNT-1 for tirzepatide), maximum weight loss efficacy occurred at maintenance doses of 1.7mg to 2.4mg weekly for semaglutide and 10mg to 15mg weekly for tirzepatide.
While Henry Meds advertises $297/month for semaglutide, their fine print restricts that price to doses of 1.0mg/week or less. The moment your physician titrates you to 1.7mg or 2.0mg+ weekly in Month 4, Henry Meds increases your monthly bill by $100/month (to $397/mo). At Telehealth FX, 0.25mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg all cost the exact same $49/month flat rate.
3. Bulk Multi-Month Vial Billing vs. Monthly Cold-Chain Freshness
Henry Meds frequently ships a single 90-day multi-puncture vial while continuing to bill your credit card $297 every 30 days. If a patient stops therapy in Month 2, they are often told they remain financially responsible for the remainder of the 90-day vial cycle. Telehealth FX provides transparent month-to-month fulfillment with fresh, potency-verified cold-chain shipments and zero multi-month billing traps.
Which Provider Fits Your Clinical Situation?
Switch to Telehealth FX. Upload a photo of your current Henry Meds vial during our 60-second intake to keep your exact dosage while cutting your monthly bill to $49 (Sema) or $99 (Tirz).
Choose Telehealth FX. Avoid Henry Meds' +$100/month high-dose surcharge ($397/mo) with our locked $49/month Price Freeze Guarantee across 1.7mg and 2.4mg tiers.
Choose Telehealth FX. Skip the 5-to-7 day wait for a scheduled Zoom call; our board-certified physicians review your chart within 24 hours and ship via 2-day cold chain.
Consider Henry Meds if you specifically want a scheduled 15-minute video appointment prior to prescribing and are comfortable paying an extra $248 to $350 per month.
Frequently Asked Questions: Telehealth FX vs Henry Meds
Is the compounded medication from Telehealth FX identical to Henry Meds?
Yes. Both platforms fulfill prescriptions exclusively through state-board-licensed 503A US compounding pharmacies operating under 21 U.S.C. § 353a and USP <797> sterile cleanroom standards, utilizing pure base semaglutide and tirzepatide.
Why does Henry Meds charge $100 extra per month for higher doses?
Henry Meds structures its $297/mo pricing around starter and intermediate doses up to 1.0mg/week, adding a $100/mo surcharge ($397/mo total) for 1.7mg–2.4mg maintenance doses. Telehealth FX eliminates dose-tier pricing entirely, keeping all semaglutide doses at $49/month flat.
Can I transfer my current Henry Meds dose without starting over at 0.25mg?
Yes. Upload a clear photo of your active Henry Meds prescription vial during our 60-second online intake, and our physicians will match your current maintenance tier seamlessly.
Are doctor consultations, syringes, and 2-day cold shipping included in the $49 rate?
Yes. Your $49/mo Semaglutide or $99/mo Tirzepatide flat rate is 100% all-inclusive: physician evaluation, prescription fulfillment, sterile insulin syringes, alcohol prep pads, and 2-day insulated cold-chain delivery are all included with $0 hidden fees.
Switch to Telehealth FX Today
Same active incretin molecules, same 503A sterile standards, but at honest flat-rate pricing. Get started online in under 3 minutes.
Check Your Eligibility NowPeer-Reviewed Clinical & Regulatory References
- Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). The New England Journal of Medicine, 384(11), 989–1002. [PubMed PMID: 33567185 ↗]
- Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). The New England Journal of Medicine, 387(3), 205–216. [PubMed PMID: 35658024 ↗]
- U.S. Food and Drug Administration (FDA). (2024). Human Drug Compounding: Section 503A of the Federal Food, Drug, and Cosmetic Act. 21 U.S.C. § 353a. [FDA Compounding Regulations & Laws ↗]
- Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial). The New England Journal of Medicine, 389(24), 2221–2232. [PubMed PMID: 37952131 ↗]
- United States Pharmacopeial Convention. (2023). USP General Chapter 797: Pharmaceutical Compounding — Sterile Preparations. [FDA & USP Compounding Standards ↗]